Practical Recommendations for the Treatment of Ascites and Its Complications

[1]  Wang Wei.  Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites , 2008 .

[2]  V. Arroyo,et al.  Prognostic value of spontaneous hyponatremia in cirrhosis with ascites , 1976, The American Journal of Digestive Diseases.

[3]  V. Arroyo,et al.  Spontaneous bacterial peritonitis in liver cirrhosis: Treatment and prophylaxis , 2005, Infection.

[4]  T. M. Mcahland.  Transjugular Intrahepatic Portosystemic Shunt in Hepatorenal Syndrome , 1999, American Journal of Gastroenterology.

[5]  A. Flahault,et al.  Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. , 1998, Journal of hepatology.

[6]  T. Poynard,et al.  Antibiotic Prophylaxis for the Prevention of Bacterial Infections in Cirrhotic Patients with Ascites: A Meta-Analysis , 1998, Digestion.

[7]  W. Jiménez,et al.  Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion , 1998, Hepatology.

[8]  W. Jiménez,et al.  Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo. , 1997, Journal of hepatology.

[9]  M. Andreu,et al.  Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin , 1997, Hepatology.

[10]  J. Llovet,et al.  Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis , 1996 .

[11]  W. Jiménez,et al.  Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. , 1996, Gastroenterology.

[12]  M. Färkkilä,et al.  The metabolism of cholestanol in primary biliary cirrhosis. , 1996, Journal of hepatology.

[13]  A. Sanyal,et al.  Tips for the treatment of refractory ascites. , 1996, Gastroenterology.

[14]  E. Keeffe,et al.  Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients , 1996, Hepatology.

[15]  J. Schölmerich,et al.  Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis , 1996, Hepatology.

[16]  M. Epstein.  The Kidney in liver disease , 1996 .

[17]  Y. Bacq,et al.  Ciprofloxacin and long‐term prevention of spontaneous bacterial peritonitis: Results of a prospective controlled trial , 1995, Hepatology.

[18]  W. Jiménez,et al.  Aquaretic effect of the kappa-opioid agonist RU 51599 in cirrhotic rats with ascites and water retention. , 1995, Gastroenterology.

[19]  V. Arroyo,et al.  Treatment of patients with cirrhosis and refractory ascites using LeVeen shunt with titanium tip: Comparison with therapeutic paracentesis , 1995, Hepatology.

[20]  M. Sherman,et al.  Transjugular Intrahepatic Portosystemic Stent Shunt: Effects on Hemodynamics and Sodium Homeostasis in Cirrhosis and Refractory Ascites , 1995, Annals of Internal Medicine.

[21]  M. Langer,et al.  The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. , 1995, The New England journal of medicine.

[22]  B. Sangro,et al.  Transjugular intrahepatic portal‐systemic shunt in the treatment of refractory ascites: Effect on clinical, renal, humoral, and hemodynamic parameters , 1995, Hepatology.

[23]  J. Lake,et al.  Transjugular intrahepatic portosystemic shunts for refractory ascites: Assessment of clinical and hormonal response and renal function , 1995, Hepatology.

[24]  M. Navasa,et al.  Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: Results of a prospective, randomized, multicenter study , 1995, Hepatology.

[25]  Y. Yamamura,et al.  Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men. , 1995, The Journal of pharmacology and experimental therapeutics.

[26]  A. Burroughs.  Treatments in hepatology , 1995 .

[27]  K. Okada,et al.  Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats. , 1994, Kidney international.

[28]  B. Campillo,et al.  Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis , 1994, Antimicrobial Agents and Chemotherapy.

[29]  X. Forns,et al.  Management of Ascites and Renal Failure in Cirrhosis , 1994, Seminars in liver disease.

[30]  P. Angeli,et al.  Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites , 1994, Hepatology.

[31]  W. Jiménez,et al.  Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. , 1993, Gastroenterology.

[32]  M. Andreu,et al.  Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. , 1993, Gastroenterology.

[33]  M. Maynar,et al.  Transjugular intrahepatic portosystemic shunt , 1993 .

[34]  X. Cussó,et al.  Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. , 1992, Gastroenterology.

[35]  J. Llach,et al.  Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: Relevance of ascitic fluid protein concentration , 1992, Hepatology.

[36]  B. Schneeweiss,et al.  Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis: Effects on renal hemodynamics and atrial natriuretic factor , 1991 .

[37]  V. Arroyo,et al.  Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. , 1991, The New England journal of medicine.

[38]  J. Such,et al.  Selective intestinal decontamination prevents spontaneous bacterial peritonitis. , 1991, Gastroenterology.

[39]  J. Llach,et al.  Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double‐blind, placebo‐controlled trial , 1990, Hepatology.

[40]  J. Llach,et al.  Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. , 1990, Gastroenterology.

[41]  Vicente Arroyo,et al.  Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis , 1988, Hepatology.

[42]  J. Llach,et al.  Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. , 1988, Gastroenterology.

[43]  J. Llach,et al.  Recurrence of spontaneous bacterial peritonitis in cirrhosis: Frequency and predictive factors , 1988, Hepatology.

[44]  W. Jiménez,et al.  Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. , 1987, Gastroenterology.

[45]  V. Arroyo,et al.  Compensated cirrhosis: Natural history and prognostic factors , 1987, Hepatology.

[46]  V. Arroyo,et al.  Cefotaxime is more effective than is ampicillin‐tobramycin in cirrhotics with severe infections , 1985, Hepatology.

[47]  V. Arroyo,et al.  Oral, nonabsorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage , 1985, Hepatology.

[48]  W. Pommer,et al.  Haemodialysis in 'hepatorenal syndrome': report on two cases. , 1985, Gut.

[49]  F. Iber,et al.  Hepatology: A Textbook of Liver Disease , 1983 .

[50]  V. Arroyo,et al.  Aminoglycoside nephrotoxicity in cirrhosis: Value of urinary β2-microglobulin to discriminate functional renal failure from acute tubular damage , 1982 .

[51]  V. Arroyo,et al.  Aminoglycoside nephrotoxicity in cirrhosis. Value of urinary beta 2-microglobulin to discriminate functional renal failure from acute tubular damage. , 1982, Gastroenterology.

[52]  T. R. Pladson,et al.  Hepatorenal syndrome. Recovery after peritoneovenous shunt. , 1977, Archives of internal medicine.

[53]  R. Zusman,et al.  The treatment of the hepatorenal syndrome with intra-renal administration of prostaglandin E1. , 1977, Prostaglandins.

[54]  P. Numann,et al.  Functional renal failure in cirrhosis. Recovery after portacaval shunt. , 1970, Annals of internal medicine.

[55]  F. Lieberman.  Functional renal failure in cirrhosis. , 1970, Gastroenterology.